The purpose of this study is to determine the safety and tolerability of NGM282, both single dose and multiple doses, in normal healthy adult participants.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
119
NGM Clinical Study Site
Perth, Western Australia, Australia
Safety and tolerability
To evaluate the safety and tolerability of single ascending doses and multiple ascending doses of NGM282 in healthy adult participants.
Time frame: 7 days and 14 days
Pharmacokinetics
To evaluate the pharmacokinetics of single ascending doses and multiple ascending doses of NGM282 in healthy adult participants.
Time frame: 7 days and 14 days
Pharmacodynamics
To evaluate the pharmacodynamics of single ascending doses and multiple ascending doses of NGM282 in healthy adult participants.
Time frame: 7 days and 14 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.